INTS Stock Forecast & Price Target

Intensity Therapeutics is attractive because its lead INT230-6 platform is showing clinical validation in two important settings, with INVINCIBLE-3 restarting enrollment after the April 2026 pause and INVINCIBLE-4 delivering early efficacy and tolerability signals. In the first 14 patients, pCR was 71% in Cohort A versus 42% in Cohort B, with a 44% reduction in grade 3 adverse events, while the company also reported no revenues and a net loss of $0.13 per diluted share in 2Q26. Although dilution remains a risk, its $9.5M cash balance and expected funding into 1H27 support continued development, and the amended protocols should improve both patient selection and response assessment.

Intensity Therapeutics is facing a fundamentally weak financial profile, with projected 2026E full-year net losses of $12.6 million, or ($4.25) per share, after an already sizable $11.6 million loss in 2025. Liquidity also looks fragile, as the company ended the third quarter with just $8.5 million in cash despite raising $3.2 million under a $60 million at-the-market equity facility established in March 2026, suggesting continued dependence on external financing. On top of that, the business still faces material regulatory uncertainty, strong competition from larger rivals, and a lack of profitability, all of which raise execution risk for its late-stage clinical platform and INT230-6 program.